A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

Go Back to All Clinical Trials

A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

Brief description of study

This is a Phase 1, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB680 (CD73 inhibitor) in combination with AB122 (programmed cell death-1 inhibitor) and standard chemotherapy (nab-paclitaxel [NP] and gemcitabine [Gem]) in participants with advanced pancreatic cancer.

Clinical Study Identifier: s19-01021

ClinicalTrials.gov Identifier: NCT04104672

Principal Investigator: Paul E. Oberstein.

Other Investigators: Shun Yu, Nina Beri, Kristen Spencer, Daniel J Becker, Jennifer Chuy.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies